ArticleClinical cancer research : an official journal of the American Association for Cancer Research2021
NRF2 Activation Promotes Aggressive Lung Cancer and Associates with Poor Clinical Outcomes.
Open access · bronzeAbstract read
In one paragraph
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 106 papers.
0numbers the graph read from it
0cells of the map it votes in
106citing papers in PubMed
8.4field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
106 citing papers in PubMed, 170 citations in OpenAlex.
- Sotorasib for Lung Cancers withThe New England journal of medicine · 2021Trial
- Molecular insights and therapeutic implications for the tumor suppressor role of LKB1 in non-small cell lung cancer.Cancer letters · 2026Review
- NRF2 activation is required for chemotherapy resistance acquisition in medulloblastoma via metabolic and redox adaptation.Redox biology · 2026Article
- Reprogramming resistance in advanced lung cancer: epigenetic modulation to restore therapeutic vulnerability.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- HNF4α controls growth, identity, and KRAS inhibitor response in invasive mucinous adenocarcinoma of the lung.The Journal of clinical investigation · 2026Article
- Identification ofMolecular medicine reports · 2026Article
- A Covalent Allosteric Molecular Glue Suppresses NRF2-Dependent Cancer Growth.Cancer discovery · 2026Article
- Characterization and therapeutic suppression of KEAP1-NRF2-driven resistance to KRAS inhibitors in pancreatic and lung cancer.bioRxiv : the preprint server for biology · 2026Article
- Marrow leptin-LEPR signaling rewires mitochondrial oxidative metabolism to confer chemoresistance in acute myeloid leukemia.Cell death & disease · 2026Article
- NRF2 pathway activation predicts poor prognosis in lung cancer: a cautionary note on antioxidant interventions.GeroScience · 2026Article
- Targeting metabolic-epigenetic-immune axis in cancer: molecular mechanisms and therapeutic implications.Signal transduction and targeted therapy · 2026Review
- Targeting Lung Cancer Metabolism: Therapeutic Opportunities and Challenges.Advances in experimental medicine and biology · 2026Review
- Functional characterization of tumor-specific CRISPR-directed gene editing as a combinatorial therapy for the treatment of solid tumors.Molecular therapy. Oncology · 2025Article
- Targeting KRAS mutations: orchestrating cancer evolution and therapeutic challenges.Signal transduction and targeted therapy · 2025Review
- Synthetic Oleanane Triterpenoids Reduce Tumor Growth and Promote an Anti-Tumor Immune Response Independent of CancerAntioxidants (Basel, Switzerland) · 2025Article
- Treatment of NSCLC after chemoimmunotherapy - are we making headway?Nature reviews. Clinical oncology · 2025Review
- NRF2 activation in cancer cells suppresses immune infiltration into the tumor microenvironment.iScience · 2025Article
- NRF2 immunobiology in cancer: implications for immunotherapy and therapeutic targeting.Oncogene · 2025Review
- Article
- Nrf2 Drives Epigenetic Reprogramming and Acts as the Master Regulator of KLF4 Expression and Activity in Arsenic-Induced Transformation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
46 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 8 institutions in 5 countries.
Anju Singh *Department of Environmental Health Science and Engineering, Johns Hopkins University School of Public Health, Baltimore, Maryland.
Anneleen Daemen *Oncology Bioinformatics, Genentech Inc., South San Francisco, California. nicklesd@gene.com anneleen.daemen@gmail.com sbiswal@jhu.edu.
Dorothee Nickles *Oncology Bioinformatics, Genentech Inc., South San Francisco, California. nicklesd@gene.com anneleen.daemen@gmail.com sbiswal@jhu.edu.
Sang-Min Jeon *Translational Oncology, Genentech Inc., South San Francisco, California.ORCID 0000-0002-0132-925X
Oded ForemanPathology, Genentech Inc., South San Francisco, California.ORCID 0000-0001-8197-3186
Kuladeep SudiniDepartment of Environmental Health Science and Engineering, Johns Hopkins University School of Public Health, Baltimore, Maryland.
Florian GnadOncology Bioinformatics, Genentech Inc., South San Francisco, California.
Stephane LajoieDepartment of Environmental Health Science and Engineering, Johns Hopkins University School of Public Health, Baltimore, Maryland.
Naina GourDepartment of Environmental Health Science and Engineering, Johns Hopkins University School of Public Health, Baltimore, Maryland.
Wayne MitznerDepartment of Environmental Health Science and Engineering, Johns Hopkins University School of Public Health, Baltimore, Maryland.ORCID 0000-0003-1615-4090
Samit ChatterjeeDepartment of Environmental Health Science and Engineering, Johns Hopkins University School of Public Health, Baltimore, Maryland.
Eun-Ji ChoiCollege of Pharmacy and Research Institute of Pharmaceutical Science and Technology, Ajou University, Suwon, Gyeonggi-do, Republic of Korea.
Buvana RavishankarCancer Immunology, Genentech Inc., South San Francisco, California.
Amy RappaportDiscovery Oncology, Genentech Inc., South San Francisco, California.
Namrata PatilOncology Biomarker Development, Genentech Inc., South San Francisco, California.
Mark McClelandOncology Biomarker Development, Genentech Inc., South San Francisco, California.
Leisa JohnsonDiscovery Oncology, Genentech Inc., South San Francisco, California.
George Acquaah-MensahDepartment of Pharmaceutical Sciences, Massachusetts College of Pharmacy and Health Sciences, Worcester, Massachusetts.ORCID 0000-0003-3984-8327
Edward GabrielsonDepartment of Pathology and Oncology, School of Medicine, Johns Hopkins University, Baltimore, Maryland.
Shyam BiswalDepartment of Environmental Health Science and Engineering, Johns Hopkins University School of Public Health, Baltimore, Maryland. nicklesd@gene.com anneleen.daemen@gmail.com sbiswal@jhu.edu.
Georgia HatzivassiliouTranslational Oncology, Genentech Inc., South San Francisco, California.
Johns Hopkins University · USBioinformatics Institute · SGGenesys (United States) · USBiomarker Technologies (China) · CNGene Therapy Laboratory · FRAjou University · KRLpath (United States) · USMassachusetts College of Pharmacy and Health Sciences · US
Funding
Dysregulated sensing of invertebrate tropomyosin through dectin-1 confers susceptibility to type-2-mediated allergic diseasesR01AI127644 · NIAID · JOHNS HOPKINS UNIVERSITY · PI LAJOIE, STEPHANE · 2017 to 2021
$2.0MCrosstalk of LKB1 and KEAP1 mutations in driving growth of lung adenocarcinomaR01CA206155 · NCI · JOHNS HOPKINS UNIVERSITY · PI BISWAL, SHYAM · 2016 to 2020
$2.0MAcquisition of a Carl Zeiss Lightsheet Z.1 Fluorescence MicroscopeS10OD020152 · OD · JOHNS HOPKINS UNIVERSITY · PI MCCAFFERY, J. MICHAEL · 2016 to 2016
$597kNCI NIH HHS R01 CA206155NIAID NIH HHS R01 AI127644NIH HHS S10 OD020152
Abstract
purposeStabilization of the transcription factor NRF2 through genomic alterations in EXPERIMENTAL
designWe model NRF2 activation,
resultsOur
conclusionsOur
Indexed as
AMP-Activated Protein Kinase KinasesAMP-Activated Protein KinasesAnimalsB7-H1 AntigenBiomarkers, TumorCarcinoma, Non-Small-Cell LungCell Line, TumorDisease Models, AnimalDrug Resistance, NeoplasmGene Expression ProfilingHumansImmune Checkpoint InhibitorsKaplan-Meier EstimateKelch-Like ECH-Associated Protein 1Lung NeoplasmsMiceAMP-Activated Protein Kinase KinasesAMP-Activated Protein KinasesB7-H1 AntigenBiomarkers, TumorCD274 protein, humanImmune Checkpoint InhibitorsKEAP1 protein, humanKeap1 protein, mouseKelch-Like ECH-Associated Protein 1KRAS protein, humanNFE2L2 protein, humanNfe2l2 protein, mouseNF-E2-Related Factor 2Proto-Oncogene Proteins p21(ras)STK11 protein, humanStk11 protein, mouse
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.